{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo%3B+placebo+comparator+condition",
    "query": {
      "intervention": "Placebo; placebo comparator condition"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 7747,
    "total_pages": 775,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo%3B+placebo+comparator+condition&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-26T22:58:33.180Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT05136885",
      "title": "HEALEY ALS Platform Trial - Regimen E SLS-005 - Trehalose",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Amyotrophic Lateral Sclerosis"
      ],
      "interventions": [
        {
          "name": "SLS-005",
          "type": "DRUG"
        },
        {
          "name": "Matching Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Merit E. Cudkowicz, MD",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 161,
      "start_date": "2022-02-21",
      "completion_date": "2023-08-25",
      "has_results": true,
      "last_update_posted_date": "2025-05-14",
      "last_synced_at": "2026-09-26T22:58:33.180Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05136885"
    },
    {
      "nct_id": "NCT06339034",
      "title": "Repurposing Lithium for Parkinson's Disease: a RCT",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Parkinson Disease"
      ],
      "interventions": [
        {
          "name": "Lithium",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DIETARY_SUPPLEMENT",
        "OTHER"
      ],
      "sponsor": "State University of New York at Buffalo",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "40 Years to 80 Years"
      },
      "enrollment_count": 20,
      "start_date": "2024-07-03",
      "completion_date": "2026-09",
      "has_results": false,
      "last_update_posted_date": "2026-06-16",
      "last_synced_at": "2026-09-26T22:58:33.180Z",
      "location_count": 1,
      "location_summary": "Williamsville, New York",
      "locations": [
        {
          "city": "Williamsville",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06339034"
    },
    {
      "nct_id": "NCT04777409",
      "title": "A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE Plus)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Early Alzheimer´s Disease"
      ],
      "interventions": [
        {
          "name": "Semaglutide",
          "type": "DRUG"
        },
        {
          "name": "Placebo (semaglutide)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novo Nordisk A/S",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "55 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "55 Years to 85 Years"
      },
      "enrollment_count": 1840,
      "start_date": "2021-05-18",
      "completion_date": "2026-01-30",
      "has_results": false,
      "last_update_posted_date": "2026-06-26",
      "last_synced_at": "2026-09-26T22:58:33.180Z",
      "location_count": 107,
      "location_summary": "Phoenix, Arizona • Scottsdale, Arizona • Sun City, Arizona + 85 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Sun City",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Anaheim",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04777409"
    },
    {
      "nct_id": "NCT01265498",
      "title": "The Farnesoid X Receptor (FXR) Ligand Obeticholic Acid in NASH Treatment Trial(FLINT)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Nonalcoholic Fatty Liver Disease (NAFLD)",
        "Nonalcoholic Steatohepatitis (NASH)"
      ],
      "interventions": [
        {
          "name": "obeticholic acid",
          "type": "DRUG"
        },
        {
          "name": "placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 283,
      "start_date": "2011-03",
      "completion_date": "2014-09",
      "has_results": true,
      "last_update_posted_date": "2018-04-06",
      "last_synced_at": "2026-09-26T22:58:33.180Z",
      "location_count": 9,
      "location_summary": "San Diego, California • San Francisco, California • Indianapolis, Indiana + 5 more",
      "locations": [
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "Durham",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01265498"
    },
    {
      "nct_id": "NCT05141006",
      "title": "Study of BOTOX Injections to Assess Change in Disease Activity and Adverse Events in Adult Female Participants With Interstitial Cystitis/Bladder Pain Syndrome (IC/BPS)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Interstitial Cystitis/Bladder Pain Syndrome (IC/BPS)"
      ],
      "interventions": [
        {
          "name": "BOTOX",
          "type": "DRUG"
        },
        {
          "name": "Placebo for BOTOX",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AbbVie",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 75 Years · Female only"
      },
      "enrollment_count": 83,
      "start_date": "2022-03-29",
      "completion_date": "2024-12-06",
      "has_results": false,
      "last_update_posted_date": "2025-05-06",
      "last_synced_at": "2026-09-26T22:58:33.180Z",
      "location_count": 40,
      "location_summary": "Homewood, Alabama • Mobile, Alabama • Buena Park, California + 32 more",
      "locations": [
        {
          "city": "Homewood",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Buena Park",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05141006"
    },
    {
      "nct_id": "NCT02048904",
      "title": "Use of Sitagliptin to Decrease Microalbuminuria",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Type 2 Diabetes",
        "Microalbuminuria"
      ],
      "interventions": [
        {
          "name": "Sitagliptin",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Missouri-Columbia",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 142,
      "start_date": "2014-01",
      "completion_date": "2016-06",
      "has_results": true,
      "last_update_posted_date": "2017-08-10",
      "last_synced_at": "2026-09-26T22:58:33.180Z",
      "location_count": 1,
      "location_summary": "Columbia, Missouri",
      "locations": [
        {
          "city": "Columbia",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02048904"
    },
    {
      "nct_id": "NCT03514784",
      "title": "Combination Probiotic: BB-12 With LGG (Different Doses) in Treating Children With Autism Spectrum Disorder",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Autism Spectrum Disorder",
        "Gastrointestinal Symptoms"
      ],
      "interventions": [
        {
          "name": "BB-12 with LGG (Higher Dose)",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "BB-12 with LGG (Lower Dose)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "The University of Texas Health Science Center, Houston",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "4 Years",
        "maximum_age": "16 Years",
        "sex": "ALL",
        "summary": "4 Years to 16 Years"
      },
      "enrollment_count": 100,
      "start_date": "2016-05",
      "completion_date": "2025-07-30",
      "has_results": true,
      "last_update_posted_date": "2026-09-14",
      "last_synced_at": "2026-09-26T22:58:33.180Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03514784"
    },
    {
      "nct_id": "NCT02803749",
      "title": "Buspirone in Parkinson's Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Parkinson Disease",
        "Anxiety"
      ],
      "interventions": [
        {
          "name": "Buspirone",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Rochester",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 21,
      "start_date": "2016-10",
      "completion_date": "2019-01-25",
      "has_results": true,
      "last_update_posted_date": "2020-01-02",
      "last_synced_at": "2026-09-26T22:58:33.180Z",
      "location_count": 1,
      "location_summary": "Rochester, New York",
      "locations": [
        {
          "city": "Rochester",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02803749"
    },
    {
      "nct_id": "NCT00766038",
      "title": "Recombinant Human Growth Hormone During Rehabilitation From Traumatic Brain Injury.",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Traumatic Brain Injury"
      ],
      "interventions": [
        {
          "name": "Recombinant human Growth Hormone",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Pennsylvania",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 63,
      "start_date": "2008-09",
      "completion_date": "2013-12",
      "has_results": true,
      "last_update_posted_date": "2019-11-18",
      "last_synced_at": "2026-09-26T22:58:33.180Z",
      "location_count": 3,
      "location_summary": "Bakersfield, California • Dallas, Texas",
      "locations": [
        {
          "city": "Bakersfield",
          "state": "California"
        },
        {
          "city": "Dallas",
          "state": "Texas"
        },
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00766038"
    },
    {
      "nct_id": "NCT02622958",
      "title": "Feasibility Study of PH94B Nasal Spray for Acute Treatment of Social Anxiety Disorder (SAD)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Social Anxiety Disorder"
      ],
      "interventions": [
        {
          "name": "PH94B",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Pherin Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 23,
      "start_date": "2014-03",
      "completion_date": "2015-03",
      "has_results": false,
      "last_update_posted_date": "2015-12-07",
      "last_synced_at": "2026-09-26T22:58:33.180Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02622958"
    }
  ]
}